Scinai Immunotherapeutics (SCNI) Total Debt (2018 - 2026)

Scinai Immunotherapeutics has disclosed Total Debt across 9 years of filings, most recently posting $285000.0 for Q2 2026.

• In Q2 2026, Total Debt fell 2.73% year-over-year to $285000.0; the TTM figure through Jun 2026 stood at $285000.0 (down 2.73% YoY), while the FY2025 annual figure was -$7.0 million, down 2774.23% from the prior year.
• Total Debt came in at $285000.0 for Q2 2026 at Scinai Immunotherapeutics, down from $287000.0 in the prior quarter.
• In the past five years, Total Debt ranged from a high of $23.3 million in Q2 2023 to a low of -$7.0 million in Q4 2025.
• Average Total Debt over 5 years is $9.6 million, with a median of $5.3 million recorded in 2022.
• Year-over-year, Total Debt surged 7555.14% in 2023 and plunged 2774.23% in 2025.
• Over 5 years, Total Debt stood at $20.8 million in 2022, then decreased by 7.09% to $19.4 million in 2023, then slumped by 98.66% to $260000.0 in 2024, then sank by 2774.23% to -$7.0 million in 2025, then soared by 104.1% to $285000.0 in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $285000.0 in Q2 2026, $287000.0 in Q1 2026, and -$7.0 million in Q4 2025.